Manufacturer
RANBAXY (MALAYSIA) SDN BHD
Contents
Gliclazide
Indication
Type 2 diabetes mellitus.
Instruction
Should be taken with food.
Drug interaction
Increased hypoglycaemic effect with phenylbutazone. May decrease metabolism with chloramphenicol. May enhance effect of anticoagulant agents (e.g. warfarin). May enhance hypoglycaemic effect with other antidiabetic agents (e.g. insulin, metformin, glucagon-like peptide-1 receptor agonists, acarbose, thiazolidinediones, dipeptidyl peptidase-4 inhibitors), ß-blockers, fluconazole, salicylates, ACE inhibitors (e.g. captopril, enalapril), H2-receptor blockers, MAOIs, sulfonamides, quinolone antibiotics, clarithromycin, and other NSAIDs. Increased blood glucose levels with chlorpromazine (at high doses), ß-agonists (e.g. salbutamol, ritodrine), tetracosactrin, glucocorticoids (with possible ketosis), and danazol.Potentially Fatal: Increased hypoglycaemic effect and possible onset of hypoglycaemia, or coma with miconazole.
Malaysia
